Annual Synagis® (palivizumab) distribution program

September 14, 2020

The 2020-2021 respiratory syncytial virus (RSV) season runs from November 1, 2020, through March 31, 2021. RSV is the most common cause of bronchiolitis and pneumonia among children younger than one year. This season, PerformSpecialty®, an independent company, will facilitate delivery of the drug Synagis® (palivizumab) through Independence’s Direct Ship Drug Program.

As a reminder, it is mandatory for all participating providers to obtain Synagis for their patients who are Independence members through our Direct Ship Drug Program. The 2020-2021 Synagis order form will be online in the next few weeks. Please do not submit forms from previous Synagis seasons, as those forms will not be accepted.

As the RSV season gets closer, we will publish an additional Partners in Health UpdateSM article to provide more detailed information on Synagis distribution.

Learn more

Additional information about Synagis can be found in the Independence Medical Policy #08.00.22m: Immune Prophylaxis for Respiratory Syncytial Virus (RSV). To view this policy, visit our Medical Policy Portal.

If you have questions about Synagis , please call Customer Service at 1-800-ASK-BLUE (1-800-275-2583).